Sunshine Healthcare Lanka Limited Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: Sunshine Healthcare Lanka Limited Pharmaceutical Import Records from India — 11 Products, $22.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sunshine Healthcare Lanka Limited — Pharmaceutical Importer Profile (2026) | 11 Products, $22.5M Trade | TransData Nexus

Sunshine Healthcare Lanka Limited

Pharmaceutical Importer · Sri Lanka · Cardiovascular Focus · $22.5M Total Trade · DGFT Verified

Sunshine Healthcare Lanka Limited is a pharmaceutical importer based in Sri Lanka with a total trade value of $22.5M across 11 products in 8 therapeutic categories. Based on 572 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sunshine Healthcare Lanka Limited sources from 23 verified Indian suppliers, with Zydus Lifesciences Limited accounting for 51.8% of imports.

Sunshine Healthcare Lanka Limited — Import Portfolio & Supplier Network

Sunshine Healthcare Lanka Limited import network — 11 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sunshine Healthcare Lanka Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zydus Lifesciences Limited	$20.9M	1,363	51.8%
Cadila Healthcare Limited	$6.6M	474	16.3%
Cadila Pharmaceuticals Limited

What Formulations Does Sunshine Healthcare Lanka Limited Import?

Formulation	Value	Ships
Candid b cream 15GM	$678.2K	15
Udiliv 300 MG tablet 15	$462.7K	18
Deriphyllin retard 150MG TAB	$434.0K	13
Pantodac 20MG tabs (pantoprazole)	$407.8K	9
Atorva 20 TAB 10x10 tablets(atorvastatincalcium)(10x10)	$399.6K	8
Cremaffin plain 225 ML	$380.0K	9
Atorva 40 TAB. (10x10) (atorvastatin	$350.0K	7
Deriphyllin retard 150MG TAB(etophylline77% & theophylline 23%)(1x300)	$346.4K	14
Atorva 40 TAB. (10x10)(atorvastatin calcium)(10 x 10 t)	$339.8K	8
Digene tablet mint 15	$318.4K	14
Atorva 10 TAB 10x10 tablets(atorvastatincalcium)(10x10)	$316.5K	9
Digene mint tablet 15	$310.9K	11
Cremaffin plus 225 ML	$297.7K	11
Zyrova 10MG tablets (rosuvastatin)	$294.7K	7
Zyrova 20 tablets (rosuvastatin)	$291.7K	8

Sunshine Healthcare Lanka Limited imports 1,522 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 11 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Atorvastatin	Cardiovascular	$5.5M	110	0.5%	16
2	Calcium	Vitamins & Supplements	$4.5M	90	0.5%	12
3	Losartan	Cardiovascular	$4.3M	88	1.4%	8
4	Pantoprazole	Gastrointestinal	$3.0M	59	0.2%	13
5	Theophylline	Respiratory	$2.1M	71	13.7%	2
6	Celecoxib	Analgesics & Antipyretics	$1.4M	40	1.0%	15
7	Formoterol	Respiratory	$582.0K	45	1.0%	16
8	Dextromethorphan	Respiratory & OTC	$413.4K	9	2.8%	5
9	Brufen	Brand Names & OTC Products	$336.3K	22	7.5%	5
10	Mebendazole	Antimalarial & Antiparasitic	$247.5K	14	1.8%	9
11	Ranitidine	Gastrointestinal	$154.4K	24	1.2%	14

Sunshine Healthcare Lanka Limited imports 11 pharmaceutical products across 8 categories into Sri Lanka totaling $22.5M.

Sunshine Healthcare Lanka Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sunshine Healthcare Lanka Limited, established in 1967, is Sri Lanka's first fully integrated healthcare company, encompassing pharmaceutical manufacturing, importation, distribution, and retailing. Headquartered in Colombo, the company operates under the umbrella of Sunshine Holdings PLC, a diversified conglomerate with interests in healthcare, consumer goods, and agribusiness. Sunshine Healthcare serves as a pivotal player in Sri Lanka's pharmaceutical distribution network, representing over 30 international companies, including Abbott Laboratories, Zydus Cadila, and Galderma. (sunshineholdings.lk)

The company's comprehensive operations span the entire pharmaceutical value chain, from research and development to last-mile distribution across the country. This integrated approach enables Sunshine Healthcare to maintain a significant presence in the Sri Lankan market, holding a 12% share of the private pharmaceutical sector. (sunshineholdings.lk) Their diverse product portfolio includes prescription and over-the-counter drugs, catering to various therapeutic areas such as dermatology, diabetes, cardiovascular health, gastrointestinal disorders, and pain management. (sunshineholdings.lk)

2Distribution Network

Sunshine Healthcare Lanka Limited boasts an extensive distribution network that ensures nationwide coverage of pharmaceutical products. The company operates multiple warehouses strategically located to facilitate efficient logistics and timely delivery. Their distribution infrastructure is designed to meet the stringent requirements of regulatory authorities and international principals, incorporating quality management systems and periodic internal audits to maintain high standards. (sunshineholdings.lk)

The company's logistics capabilities are robust, supporting a wide range of customer channels, including retail pharmacies, modern trade, hospitals, and government tenders. This comprehensive distribution system underscores Sunshine Healthcare's commitment to making quality medicines accessible to all Sri Lankans, thereby enhancing the overall healthcare landscape of the country. (sunshineholdings.lk)

3Industry Role

Sunshine Healthcare Lanka Limited plays a multifaceted role in Sri Lanka's pharmaceutical supply chain. As a primary wholesaler, the company imports and distributes a diverse array of pharmaceutical products, ensuring their availability across various healthcare settings. Additionally, Sunshine Healthcare serves as a parallel importer, sourcing products from international markets to meet local demand. Their extensive partnerships with global pharmaceutical companies enable them to supply a wide range of medicines, including those not readily available through other channels. (sunshineholdings.lk)

Furthermore, Sunshine Healthcare acts as a hospital supplier, providing essential medicines and medical devices to both public and private healthcare institutions. Their involvement in government tenders and supply to government-owned pharmacy chains, such as the State Pharmaceutical Corporation (SPC) and Osu Sala, highlights their significant role in the public healthcare sector. (sunshineholdings.lk)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sunshine Healthcare Lanka Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sunshine Healthcare Lanka Limited's sourcing strategy exhibits a high degree of concentration, with the top five products accounting for 86.2% of their total import value from India. This concentration indicates a strategic focus on key therapeutic areas, particularly in cardiovascular, vitamins and supplements, and gastrointestinal categories. The substantial import values of Atorvastatin ($5.5M), Calcium ($4.5M), Losartan ($4.3M), Pantoprazole ($3.0M), and Theophylline ($2.1M) underscore the company's emphasis on these segments.

The dominance of a few products suggests a deliberate sourcing approach aimed at meeting the most pressing healthcare needs in Sri Lanka. However, this concentration also implies potential risks, such as supply chain disruptions affecting these critical products. The company's reliance on a limited number of suppliers for these items may impact the stability and resilience of their supply chain.

2Supply Chain Resilience

Sunshine Healthcare Lanka Limited's supply chain resilience is closely tied to its sourcing concentration. The company's dependence on a select group of suppliers for its top five imported products necessitates robust risk management strategies to mitigate potential disruptions. While the company has established long-term partnerships with reputable Indian pharmaceutical manufacturers, the limited number of suppliers for key products could pose challenges in maintaining a consistent supply.

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

In Sri Lanka, the National Medicines Regulatory Authority (NMRA) serves as the primary regulatory body overseeing the registration, importation, and distribution of pharmaceutical products. The NMRA is responsible for ensuring the quality, safety, and efficacy of medicines available in the country. Key legislation governing pharmaceutical imports includes the National Medicines Regulatory Authority Act, which outlines the procedures for drug registration, import control, and market surveillance. (nmra.gov.lk)

The NMRA's Medicines Evaluation Committee (MEC) conducts scientific and technical reviews of medicines submitted for registration, ensuring compliance with established standards. This committee plays a crucial role in maintaining the integrity of the pharmaceutical supply chain by evaluating the quality and safety of medicinal products. (nmra.gov.lk)

2Import Licensing & GMP

To import pharmaceutical products into Sri Lanka, companies must obtain an import license from the NMRA. This process involves submitting detailed product information, including Certificates of Pharmaceutical Product (COPP), Certificates of Analysis (COA), and Batch Release Certificates. Additionally, the NMRA requires that imported medicines comply with Good Manufacturing Practice (GMP) standards recognized by international bodies such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). (nmra.gov.lk)

Sunshine Healthcare Lanka Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sunshine Healthcare Lanka Limited's product strategy focuses on therapeutic areas with high prevalence and unmet needs in Sri Lanka, such as cardiovascular diseases, vitamin deficiencies, and gastrointestinal disorders. By concentrating on these segments, the company addresses critical health concerns and aligns its offerings with the demands of the local market. The substantial import values of key products like Atorvastatin, Calcium, Losartan, Pantoprazole, and Theophylline reflect this strategic focus.

The company's emphasis on these therapeutic areas is driven by market demand and the opportunity to provide effective solutions to prevalent health issues. By offering a range of products in these categories, Sunshine Healthcare enhances its competitive position and contributes to improving public health outcomes in Sri Lanka.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Sunshine Healthcare Lanka Limited

What products does Sunshine Healthcare Lanka Limited import from India?

Sunshine Healthcare Lanka Limited imports 11 pharmaceutical products across 8 categories. Top imports: Atorvastatin ($5.5M), Calcium ($4.5M), Losartan ($4.3M), Pantoprazole ($3.0M), Theophylline ($2.1M).

Who supplies pharmaceuticals to Sunshine Healthcare Lanka Limited from India?

Sunshine Healthcare Lanka Limited sources from 23 verified Indian suppliers. The primary supplier is Zydus Lifesciences Limited (51.8% of imports, $20.9M).

What is Sunshine Healthcare Lanka Limited's total pharmaceutical import value?

Sunshine Healthcare Lanka Limited's total pharmaceutical import value from India is $22.5M, based on 572 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sunshine Healthcare Lanka Limited focus on?

Sunshine Healthcare Lanka Limited imports across 8 categories. The largest: Cardiovascular (43.5%), Vitamins & Supplements (20.0%), Gastrointestinal (13.8%).

Get Full Sunshine Healthcare Lanka Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.